Retour
Prix Alterity Therapeutics Limited (PRNAF)
Graphique du cours de l'action PRNAF
PRNAF Gagner
Alterity Therapeutics Limited
$0
0%
$0
À la fermeture : Feb 06, 16:00:00 GMT-5
$0
0%
$0
Post-Marché: Feb 06, 20:00:00 GMT-5
Earnings FAQ
Comment le bénéfice par action récent de PRNAF se compare-t-il aux attentes ?
Comment les revenus de Alterity Therapeutics Limited PRNAF se sont-ils comportés au dernier trimestre ?
Quelle est l'estimation des revenus pour Alterity Therapeutics Limited ?
Quel est le score de qualité des bénéfices pour Alterity Therapeutics Limited ?
Quand Alterity Therapeutics Limited publie-t-elle ses résultats ?
Quels sont les bénéfices attendus de Alterity Therapeutics Limited ?
Alterity Therapeutics Limited a-t-elle dépassé les attentes en matière de bénéfices ?
Statistiques clés
Clôture préc.
$0.0097
Prix d'ouverture
$0.0097
Plage de la journée
$0.0097 - $0.0097
Plage de 52 semaines
$0.003 - $0.0139
Volume
10.0K
Volume moyen
331
BPA (TTM)
0.00
Rendement en dividend
--
Capitalisation boursière
$105.4M
Qu’est-ce que Alterity Therapeutics Limited ?
Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.
Fonctionnalités
Stratégies de trading
Ressources
© 2025 Finture Development Limited. All rights reserved